Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma.
Masayuki ImayaHideki MuramatsuAtsushi NaritaAyako YamamoriManabu WakamatsuTaro YoshidaShunsuke MiwataKotaro NaritaDaisuke IchikawaMotoharu HamadaEri NishikawaNozomu KawashimaNobuhiro NishioSeiji KojimaYoshiyuki TakahashiPublished in: Cancer medicine (2022)
IREC showed an objective response rate of 15% including 1 case with partial response. IREC was well tolerated regardless of UGT1A1 genotype. This study suggests that IREC is a promising second-line chemotherapy for refractory or relapsed neuroblastoma.